SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.

   Biotech / MedicalDEMEGEN (DBOT) $.29 LAUNCHES IR CAMPAIGN


Next 10 
To: Stock Master who wrote ()4/13/1999 7:09:00 PM
From: Stock Master
   of 11
 
UNIVERSITY OF PITTSBURGH REPORTS EXCITING PRECLINICAL RESULTS WITH DEMEGEN'S PEPTIDE TO THE AMERICAN ASSOCIATION FOR CANCER RESEARCH
PITTSBURGH, PA - April 13, 1999: Demegen, Inc. (OTC BB: DBOT) announced today that the University of Pittsburgh Cancer Institute (UPCI) is presenting results of preclinical studies using the Company's patented D2A21 peptide at this afternoon's annual meeting of the American Association for Cancer Research in Philadelphia, Pa. The report highlighted the new agent's promise against both aggressive and slow-growing prostate cancer types.
Demegen's D2A21 peptide is a laboratory-synthesized small compound that destroys a cancer cell by attaching to its surface and disrupting its outer membrane. At therapeutic doses, D2A21 is designed to target and lyse (eliminate) cancer cells, sparing the normal healthy cells and tissues.
Results of UPCI preclinical studies show the D2A21 compound was effective using several routes of administration, including intravenous, subcutaneous, and oral. Treatment with D2A21 did not cause any significant toxicities, according to the researchers who are now conducting additional preclinical studies in preparation for testing Demegen's compound in cancer patients.
“This agent represents a totally new way to attack cancer,” said Robert Getzenberg, Ph.D., principal investigator and assistant professor of pathology, pharmacology, medicine, and surgery who co-directs UPCI's Prostate and Urologic Cancer Center. “We're particularly encouraged that this agent is effective against metastatic prostate cancer, which is notoriously difficult to treat.”
In the preclinical experiments conducted at UPCI, investigators used Demegen's D2A21 to treat established aggressive prostate cancers in rats. The researchers found that D2A21 inhibited tumor growth by as much as 60 percent as compared to untreated animals.
In another experiment, researchers injected a group of rats with typically lethal numbers of cancer cells and simultaneously treated them with D2A21. Results showed that 75 percent of animals receiving D2A21 survived versus only 25 percent of animals that did not receive the peptide treatment. D2A21 was also able to reduce lung metastases by 90 percent.
Commenting on the report, Demegen CEO Richard Ekstrom stated, “We are very pleased with the results of studies conducted thus far at the University of Pittsburgh Cancer Institute. We look forward to continued reports from the researchers as they proceed towards human clinical trials.”
Demegen, Inc., founded in 1992, is a research and development firm that designs novel synthetic molecules for the treatment of cancer and infectious diseases as well as disease resistant and nutritionally enhanced commercial crops. The Company currently generates revenues through licenses for two broad applications of its patented technologies to Dow AgroSciences LLC.
Forward-looking statements in this release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including but not limited to, results of research and development, the U.S. Food and Drug Administration and other regulatory agencies, increased competition, product development and commercialization, and other risks detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Stock Master who wrote (1)4/15/1999 2:38:00 PM
From: Stock Master
   of 11
 
DBOT RUNNING ON VOLUME BREAKOUT $.55 UP $.05 ON ALMOST 400,000 SHARES

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Stock Master who wrote (2)5/5/1999 7:14:00 PM
From: priceguy
   of 11
 
What is happening? Virtually no volume and no price movement in two weeks. Any news?

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: priceguy who wrote (3)5/9/1999 1:07:00 PM
From: Angler
   of 11
 
Priceguy:

This little acorn is well planted. At least it's not 100% in the red. So now all we have to do is stick around and watch a tree grow.

Angler

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Angler who wrote (4)5/14/1999 8:03:00 PM
From: priceguy
   of 11
 
Another week has passed with no news..and trading next to no shares daily..I have tried emailing the firm to ask what is happening..they do not reply. Does anyone know anything? April's releases sounded so good and then dead silence. Very strange. I will try telephoning on Monday if this gets no response.

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


To: priceguy who wrote (5)5/15/1999 12:44:00 PM
From: Angler
   of 11
 
priceguy:

No news is not good news in stocks. However, this is a very tiny company. They did post their profile and balance sheet.
One really has to have patience with these venture speculative things, but for the cheap stake one should part with in the beginning, it becomes a roll of the dice. We've seen good things happen two years later but who knows? Let's hear about any phone call response.

Angler

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Angler who wrote (6)11/12/1999 7:38:00 AM
From: Henry Niman
   of 11
 
Any ideas on yesterday's price and volume spike near the close?

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


To: Henry Niman who wrote (7)11/12/1999 10:00:00 AM
From: Angler
   of 11
 
Sorry, Henry:

I haven't a clue. I put this little startup BB away in the drawer, and haven't looked at it since.
Every once in a while one of these little once comes popping up - not very often.
If you here anything, let me know.

Angler

Share RecommendKeepReplyMark as Last Read


To: Henry Niman who wrote (7)3/13/2000 9:27:00 AM
From: Angler
   of 11
 
Henry:

It's been 3 months since our last chat.

I've sold and repurchased DBOT. It "spiked" up recently now over $1.50.

I like the management of this company. Can't say I know what they're really doing; however, I can say the same about CSCO and EXDS that I also own. My attention span for details has been very poor and hasn't changed in 70 yrs.

I believe that about 5% of all penny stocks ever succeed?
This one shows promise so I will buy and sell as it goes up and if it surprises me I'll put a chunk away. $2.00 sh on growing volume is my decision point.

Are you thinking on this too?

Angler

Share RecommendKeepReplyMark as Last Read


To: priceguy who wrote (5)3/13/2000 9:30:00 AM
From: Angler
   of 11
 
Priceguy:

Are you still into this penny stock?

It appears to be gaining some momentum. Maybe insiders?

Any ideas?

Angler

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Next 10